
West Pharmaceutical Services Raises Full-Year Guidance After Strong Q2
West Pharmaceutical Services reported a 13.8% increase in second-quarter net sales to $872.3 million, buoyed by surging demand in its biologics and GLP-1 elastomer businesses. The Exton-based company subsequently raised its full-year 2026 earnings outlook, citing robust execution and favorable product mix shifts across its core segments.
























